+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oligonucleotide Therapeutics Market 2024-2028

  • PDF Icon

    Report

  • 169 Pages
  • April 2024
  • Region: Global
  • TechNavio
  • ID: 5017683
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oligonucleotide therapeutics market is forecasted to grow by USD 13443.7 million during 2023-2028, accelerating at a CAGR of 19.87% during the forecast period. The report on the oligonucleotide therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of cancer boosts demand for novel diagnostics, need for personalized medicines for neurological disorders, and increasing availability of oligonucleotide therapeutic drugs.

The oligonucleotide therapeutics market is segmented as below:

By Type

  • Antisense oligonucleotides
  • RNA interference
  • Aptamers and others

By Application

  • Neurological
  • Cancer
  • Infectious diseases and others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the advances in DNA sequencing increasing adoption of microfluidic techniques as one of the prime reasons driving the oligonucleotide therapeutics market growth during the next few years. Also, high market growth potential in developing economies and growing adoption of artificial intelligence for disease evaluation will lead to sizable demand in the market.

The report on the oligonucleotide therapeutics market covers the following areas:

  • Oligonucleotide therapeutics market sizing
  • Oligonucleotide therapeutics market forecast
  • Oligonucleotide therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oligonucleotide therapeutics market vendors that include Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Biogen Inc., CSL Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Maravai LifeSciences Holdings Inc., Merck KGaA, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.. Also, the oligonucleotide therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global oligonucleotide therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global oligonucleotide therapeutics market 2018 - 2022 ($ million)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
4.3 Application Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Application Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
6.1 Market segments
Exhibit 30: Chart on Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028
Exhibit 34: Chart on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
6.4 RNA interference (RNAi) - Market size and forecast 2023-2028
Exhibit 38: Chart on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
6.5 Aptamers and others - Market size and forecast 2023-2028
Exhibit 42: Chart on Aptamers and others - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Aptamers and others - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Aptamers and others - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Aptamers and others - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Type
Exhibit 46: Market opportunity by Type ($ million)
Exhibit 47: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Application
7.1 Market segments
Exhibit 48: Chart on Application - Market share 2023-2028 (%)
Exhibit 49: Data Table on Application - Market share 2023-2028 (%)
7.2 Comparison by Application
Exhibit 50: Chart on Comparison by Application
Exhibit 51: Data Table on Comparison by Application
7.3 Neurological - Market size and forecast 2023-2028
Exhibit 52: Chart on Neurological - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Neurological - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Neurological - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Neurological - Year-over-year growth 2023-2028 (%)
7.4 Cancer - Market size and forecast 2023-2028
Exhibit 56: Chart on Cancer - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Cancer - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Cancer - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Cancer - Year-over-year growth 2023-2028 (%)
7.5 Infectious diseases and others - Market size and forecast 2023-2028
Exhibit 60: Chart on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Application
Exhibit 64: Market opportunity by Application ($ million)
Exhibit 65: Data Table on Market opportunity by Application ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Agilent Technologies Inc.
Exhibit 115: Agilent Technologies Inc. - Overview
Exhibit 116: Agilent Technologies Inc. - Business segments
Exhibit 117: Agilent Technologies Inc. - Key news
Exhibit 118: Agilent Technologies Inc. - Key offerings
Exhibit 119: Agilent Technologies Inc. - Segment focus
12.4 Alnylam Pharmaceuticals Inc.
Exhibit 120: Alnylam Pharmaceuticals Inc. - Overview
Exhibit 121: Alnylam Pharmaceuticals Inc. - Product / Service
Exhibit 122: Alnylam Pharmaceuticals Inc. - Key offerings
12.5 Biogen Inc.
Exhibit 123: Biogen Inc. - Overview
Exhibit 124: Biogen Inc. - Product / Service
Exhibit 125: Biogen Inc. - Key news
Exhibit 126: Biogen Inc. - Key offerings
12.6 CSL Ltd.
Exhibit 127: CSL Ltd. - Overview
Exhibit 128: CSL Ltd. - Business segments
Exhibit 129: CSL Ltd. - Key news
Exhibit 130: CSL Ltd. - Key offerings
Exhibit 131: CSL Ltd. - Segment focus
12.7 GlaxoSmithKline Plc
Exhibit 132: GlaxoSmithKline Plc - Overview
Exhibit 133: GlaxoSmithKline Plc - Business segments
Exhibit 134: GlaxoSmithKline Plc - Key news
Exhibit 135: GlaxoSmithKline Plc - Key offerings
Exhibit 136: GlaxoSmithKline Plc - Segment focus
12.8 Ionis Pharmaceuticals Inc.
Exhibit 137: Ionis Pharmaceuticals Inc. - Overview
Exhibit 138: Ionis Pharmaceuticals Inc. - Business segments
Exhibit 139: Ionis Pharmaceuticals Inc. - Key news
Exhibit 140: Ionis Pharmaceuticals Inc. - Key offerings
Exhibit 141: Ionis Pharmaceuticals Inc. - Segment focus
12.9 Maravai LifeSciences Holdings Inc.
Exhibit 142: Maravai LifeSciences Holdings Inc. - Overview
Exhibit 143: Maravai LifeSciences Holdings Inc. - Business segments
Exhibit 144: Maravai LifeSciences Holdings Inc. - Key offerings
Exhibit 145: Maravai LifeSciences Holdings Inc. - Segment focus
12.10 Merck KGaA
Exhibit 146: Merck KGaA - Overview
Exhibit 147: Merck KGaA - Business segments
Exhibit 148: Merck KGaA - Key news
Exhibit 149: Merck KGaA - Key offerings
Exhibit 150: Merck KGaA - Segment focus
12.11 Nippon Shinyaku Co. Ltd.
Exhibit 151: Nippon Shinyaku Co. Ltd. - Overview
Exhibit 152: Nippon Shinyaku Co. Ltd. - Business segments
Exhibit 153: Nippon Shinyaku Co. Ltd. - Key offerings
Exhibit 154: Nippon Shinyaku Co. Ltd. - Segment focus
12.12 Novartis AG
Exhibit 155: Novartis AG - Overview
Exhibit 156: Novartis AG - Business segments
Exhibit 157: Novartis AG - Key news
Exhibit 158: Novartis AG - Key offerings
Exhibit 159: Novartis AG - Segment focus
12.13 Pfizer Inc.
Exhibit 160: Pfizer Inc. - Overview
Exhibit 161: Pfizer Inc. - Product / Service
Exhibit 162: Pfizer Inc. - Key news
Exhibit 163: Pfizer Inc. - Key offerings
12.14 Sarepta Therapeutics Inc.
Exhibit 164: Sarepta Therapeutics Inc. - Overview
Exhibit 165: Sarepta Therapeutics Inc. - Product / Service
Exhibit 166: Sarepta Therapeutics Inc. - Key offerings
12.15 Thermo Fisher Scientific Inc.
Exhibit 167: Thermo Fisher Scientific Inc. - Overview
Exhibit 168: Thermo Fisher Scientific Inc. - Business segments
Exhibit 169: Thermo Fisher Scientific Inc. - Key news
Exhibit 170: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 171: Thermo Fisher Scientific Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 172: Inclusions checklist
Exhibit 173: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 174: Currency conversion rates for US$
13.4 Research methodology
Exhibit 175: Research methodology
Exhibit 176: Validation techniques employed for market sizing
Exhibit 177: Information sources
13.5 List of abbreviations
Exhibit 178: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Application
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global oligonucleotide therapeutics market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Application Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Type - Market share 2023-2028 (%)
Exhibits 31: Data Table on Type - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Type
Exhibits 33: Data Table on Comparison by Type
Exhibits 34: Chart on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Aptamers and others - Market size and forecast 2023-2028 ($ million)
Exhibits 43: Data Table on Aptamers and others - Market size and forecast 2023-2028 ($ million)
Exhibits 44: Chart on Aptamers and others - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Aptamers and others - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by Type ($ million)
Exhibits 47: Data Table on Market opportunity by Type ($ million)
Exhibits 48: Chart on Application - Market share 2023-2028 (%)
Exhibits 49: Data Table on Application - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Application
Exhibits 51: Data Table on Comparison by Application
Exhibits 52: Chart on Neurological - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on Neurological - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on Neurological - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Neurological - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Cancer - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Cancer - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Cancer - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Cancer - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
Exhibits 61: Data Table on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
Exhibits 62: Chart on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
Exhibits 64: Market opportunity by Application ($ million)
Exhibits 65: Data Table on Market opportunity by Application ($ million)
Exhibits 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 69: Chart on Geographic comparison
Exhibits 70: Data Table on Geographic comparison
Exhibits 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 104: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 107: Market opportunity By Geographical Landscape ($ million)
Exhibits 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 109: Impact of drivers and challenges in 2023 and 2028
Exhibits 110: Overview on Criticality of inputs and Factors of differentiation
Exhibits 111: Overview on factors of disruption
Exhibits 112: Impact of key risks on business
Exhibits 113: Vendors covered
Exhibits 114: Matrix on vendor position and classification
Exhibits 115: Agilent Technologies Inc. - Overview
Exhibits 116: Agilent Technologies Inc. - Business segments
Exhibits 117: Agilent Technologies Inc. - Key news
Exhibits 118: Agilent Technologies Inc. - Key offerings
Exhibits 119: Agilent Technologies Inc. - Segment focus
Exhibits 120: Alnylam Pharmaceuticals Inc. - Overview
Exhibits 121: Alnylam Pharmaceuticals Inc. - Product / Service
Exhibits 122: Alnylam Pharmaceuticals Inc. - Key offerings
Exhibits 123: Biogen Inc. - Overview
Exhibits 124: Biogen Inc. - Product / Service
Exhibits 125: Biogen Inc. - Key news
Exhibits 126: Biogen Inc. - Key offerings
Exhibits 127: CSL Ltd. - Overview
Exhibits 128: CSL Ltd. - Business segments
Exhibits 129: CSL Ltd. - Key news
Exhibits 130: CSL Ltd. - Key offerings
Exhibits 131: CSL Ltd. - Segment focus
Exhibits 132: GlaxoSmithKline Plc - Overview
Exhibits 133: GlaxoSmithKline Plc - Business segments
Exhibits 134: GlaxoSmithKline Plc - Key news
Exhibits 135: GlaxoSmithKline Plc - Key offerings
Exhibits 136: GlaxoSmithKline Plc - Segment focus
Exhibits 137: Ionis Pharmaceuticals Inc. - Overview
Exhibits 138: Ionis Pharmaceuticals Inc. - Business segments
Exhibits 139: Ionis Pharmaceuticals Inc. - Key news
Exhibits 140: Ionis Pharmaceuticals Inc. - Key offerings
Exhibits 141: Ionis Pharmaceuticals Inc. - Segment focus
Exhibits 142: Maravai LifeSciences Holdings Inc. - Overview
Exhibits 143: Maravai LifeSciences Holdings Inc. - Business segments
Exhibits 144: Maravai LifeSciences Holdings Inc. - Key offerings
Exhibits 145: Maravai LifeSciences Holdings Inc. - Segment focus
Exhibits 146: Merck KGaA - Overview
Exhibits 147: Merck KGaA - Business segments
Exhibits 148: Merck KGaA - Key news
Exhibits 149: Merck KGaA - Key offerings
Exhibits 150: Merck KGaA - Segment focus
Exhibits 151: Nippon Shinyaku Co. Ltd. - Overview
Exhibits 152: Nippon Shinyaku Co. Ltd. - Business segments
Exhibits 153: Nippon Shinyaku Co. Ltd. - Key offerings
Exhibits 154: Nippon Shinyaku Co. Ltd. - Segment focus
Exhibits 155: Novartis AG - Overview
Exhibits 156: Novartis AG - Business segments
Exhibits 157: Novartis AG - Key news
Exhibits 158: Novartis AG - Key offerings
Exhibits 159: Novartis AG - Segment focus
Exhibits 160: Pfizer Inc. - Overview
Exhibits 161: Pfizer Inc. - Product / Service
Exhibits 162: Pfizer Inc. - Key news
Exhibits 163: Pfizer Inc. - Key offerings
Exhibits 164: Sarepta Therapeutics Inc. - Overview
Exhibits 165: Sarepta Therapeutics Inc. - Product / Service
Exhibits 166: Sarepta Therapeutics Inc. - Key offerings
Exhibits 167: Thermo Fisher Scientific Inc. - Overview
Exhibits 168: Thermo Fisher Scientific Inc. - Business segments
Exhibits 169: Thermo Fisher Scientific Inc. - Key news
Exhibits 170: Thermo Fisher Scientific Inc. - Key offerings
Exhibits 171: Thermo Fisher Scientific Inc. - Segment focus
Exhibits 172: Inclusions checklist
Exhibits 173: Exclusions checklist
Exhibits 174: Currency conversion rates for US$
Exhibits 175: Research methodology
Exhibits 176: Validation techniques employed for market sizing
Exhibits 177: Information sources
Exhibits 178: List of abbreviations

Executive Summary

The following companies are recognized as the key players in the global oligonucleotide therapeutics market: Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Biogen Inc., CSL Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Maravai LifeSciences Holdings Inc., Merck KGaA, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advances in DNA sequencing increasing adoption of microfluidic techniques."

According to the report, one of the major drivers for this market is the increasing incidence of cancer boosts demand for novel diagnostics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agilent Technologies Inc.
  • Alnylam Pharmaceuticals Inc.
  • Biogen Inc.
  • CSL Ltd.
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc.
  • Maravai LifeSciences Holdings Inc.
  • Merck KGaA
  • Nippon Shinyaku Co. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sarepta Therapeutics Inc.
  • Thermo Fisher Scientific Inc.